With shares of Wal-Mart (NYSE:WMT) trading around $72, is WMT an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s MovementWal-Mart operates retail stores in various formats around the world. The company aims to price items at the lowest price every day. Wal-Mart operates in three business segments: the Walmart U.S. segment, the Walmart International segment, and the Sam�� Club segment. It manages retail stores, restaurants, discount stores, supermarkets, supercenters, hypermarkets, warehouse clubs, apparel stores, Sam��� Clubs, neighborhood markets, and other small formats, as well as Walmart.com and Samsclub.com. Through its retail channels, Wal-Mart is able to provide a variety of products and services at very affordable prices to consumers and companies worldwide.
Wal-Mart has stopped expansion in India while the company is under two different investigations there and the government has tightened regulations on foreign-owned retail businesses. The Indian government is investigating Wal-Mart for a loan the company took out that would become equity once the government changed regulations to allow foreign ownership of front-end grocery stores. Wal-Mart is also investigating whether some of its employees in the country broke the U.S. Foreign Corrupt Practices Act by bribing officials to open stores.
Top Chemical Companies To Own In Right Now: I.D. Systems Inc.(IDSY)
I.D. Systems, Inc. develops, markets, and sells wireless solutions for managing and securing enterprise assets, including industrial vehicles, such as forklifts, airport ground support equipment, rental vehicles, and transportation assets primarily in North America. The company offers integrated wireless solutions that enable customers to control, monitor, track, and analyze their enterprise assets. Its campus-based fleet management products include On-Asset Hardware, which provides an autonomous means of asset control and monitoring; Wireless Asset Managers that link mobile assets being monitored with customer?s computer network or to a remotely hosted server; Server Software, which manages data communications between the system?s database and either the Wireless Asset Managers or On-Asset Hardware; and Client Software, which restricts access and limits corruption of system information, as well as minimizes network bandwidth usage. The company?s remote asset management products comprise On-Asset Hardware, which addresses various remote asset types, such as dry van trailers, refrigerated trailers, domestic containers, and railcars, as well as customer-specific requirements; and VeriWise Intelligence Portal, a hosted Website that provides Internet access to client asset information. The company also offers direct feed of the data to customer through XML or Web services. In addition, it provides maintenance, customer support, and consulting services. I.D. Systems markets and sells its wireless solutions to a range of customers in the commercial and government sectors operating in various markets, such as automotive manufacturing, retailers, shippers, freight transportation companies, heavy industry, retail and wholesale distribution, aerospace and defense, homeland security, and vehicle rental directly, as well as through indirect sales channels, such as industrial equipment dealers. The company was founded in 1993 and is headquartered in Wo odcliff Lake, New Jersey.
Advisors' Opinion:- [By John Udovich]
Yesterday, small cap identity protection stock Lifelock Inc (NYSE: LOCK) surged 15.64% after reporting better-than-expected third quarter earnings thanks in part to playing on the security fears of consumers, meaning its probably time to take a look at it along with two other security stocks, I.D. Systems, Inc (NASDAQ: IDSY) and View Systems Inc (OTCBB: VSYM), which can also play up the fear factor:�
Top 10 Supermarket Stocks To Buy For 2014: iShares MSCI Austria Capped ETF (EWO)
iShares MSCI Austria Index Fund (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the Austrian market, as measured by the MSCI Austria Index (the Index). The Index seeks to measure the performance of the Austrian equity market. The Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion in the Index. The Index is reviewed quarterly.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Tom Aspray]
This is quite a bit better than the 9.2% gain of the iShares MSCI Italy (EWI) or the 8.9% rise in the iShares MSCI Austria (EWO). All three have done significantly better than the Spyder Trust (SPY), which is up 3.6%. The French and German country ETFs have not yet moved above their late 2013 highs.
Top 10 Supermarket Stocks To Buy For 2014: Deutsche Boerse AG (DB1)
Deutsche Boerse AG is a Germany-based international financial marketplace operator. It operates four business segments: Xetra; Eurex; Clearstream, and Market Data & Analytics. The Xetra business segment comprises three business areas: cash market using the Xetra electronic trading system and Xetra Frankfurt specialist trading; central counterparty for equities, and admission of securities to listing. The Eurex business segment comprises four business areas: electronic derivatives market trading platform Eurex; electronic options trading platform ISE; over-the-counter trading platforms Eurex Bonds, Eurex Repo, and Eurex Clearing. The Clearstream business segment comprises three business areas: custody, administration and settlement services for securities; global securities financing services, and investment funds services. The Market Data & Analytics business segment comprises two business areas: sales of price information and information distribution, and index development and sales. Advisors' Opinion:- [By Nikolaj Gammeltoft]
IntercontinentalExchange, the energy and commodity futures bourse known as ICE, is buying the U.S. equity exchange operator as the profitability of stock trading declines and derivatives generate more income. European Union regulators approved the deal on June 24 after blocking Deutsche Boerse AG (DB1)�� purchase of NYSE last year, citing concern over competition in derivatives and clearing.
- [By Nikolaj Gammeltoft]
The mishap followed others earlier in the week. An Oct. 30 malfunction interrupted data transmission at Deutsche Boerse AG (DB1)�� International Securities Exchange, while Nasdaq was unable to distribute prices for its benchmark stock indexes for almost an hour on Oct. 29. The breakdowns refocused concern that the distribution of trading over dozens of mostly automated venues has made U.S. securities markets fundamentally flawed.
Top 10 Supermarket Stocks To Buy For 2014: Smiths Group PLC (SMGKF.PK)
Smiths Group plc is a technology company. It has five divisions: Smiths Detection, Smiths Medical, John Crane, Smiths Interconnect and Flex-Tek. The Company and its subsidiaries develop, manufacture, sale and support advanced security equipment, including trace detection, millimeter-wave, infrared, biological detection and diagnostics; mechanical seals, seal support systems, engineered bearings, power transmission couplings and specialist filtration systems, and medical devices aligned to specific therapies, principally airway, pain and temperature management, and vascular access. It also develops, manufactures, sells and supports specialized electronic and radio frequency products for the global wireless telecommunications, aerospace, defense, space, medical, rail, test and industrial markets, and engineered components, including ducting, hose assemblies and heating elements. In May 2011, it acquired the entire issued share capital of SDBR Comercio De Equipamentos De Seguanca LTDA. Advisors' Opinion:- [By Daniel Lauchheimer]
Currently, three main companies supply security equipment to the TSA - Safran (SAFRY.PK), Smiths (SMGKF.PK), and Level-3 Holdings (LLL). All three of these companies sell the whole range of their products to the TSA, with an ETD offering included. Recently, however, a new company, Implant Sciences Corporation (IMSC.PK) received approval from the TSA to begin selling their ETD equipment to airport security professionals. This approval has opened the door for IMSC to begin taking some market share away from the more established players in the US and beyond.
Top 10 Supermarket Stocks To Buy For 2014: OncoGenex Pharmaceuticals Inc.(OGXI)
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company?s clinical stage products include Custirsen, a phase III clinical stage product for treatment in men with metastatic castrate-resistant prostate cancer; OGX-427, which is in phase II clinical development stage is designed to inhibit heat shock protein 27; and SN2310 that completed phase I stage of clinical development is designed to evaluate safety in patients with advanced cancer. Its pre clinical stage products include GX-225 that is focused on reducing the production of IGFBP-2 and IGFBP-5; and CSP-9222, lead compound from a family of caspase activators. OncoGenex Pharmaceuticals, Inc. is based in Bothell, Washington.
Advisors' Opinion:- [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]
Teva Pharmaceutical Industries Ltd.(TEVA) and OncoGenex Pharmaceuticals Inc.(OGXI) said their experimental drug for hard-to-treat cases of prostate cancer didn’t result in statistically significant improvement in overall survival in a Phase 3 study. OncoGenex shares dropped 48% to $5 premarket.
Top 10 Supermarket Stocks To Buy For 2014: Metro Bancorp Inc(METR)
Metro Bancorp, Inc. operates as the bank holding company for Metro Bank, which provides a range of retail and commercial banking services to consumers and small and mid-sized companies in Pennsylvania. Its deposit products include personal and business checking accounts, regular savings accounts, money market accounts, interest checking accounts, fixed rate certificates of deposit, individual retirement accounts, and club accounts. The company?s loan products portfolio comprises commercial and industrial, owner occupied real estate, commercial construction and land development, and commercial real estate loans; consumer loans, including home equity, overdraft checking protection, and consumer credit cards, as well as installment loans for home improvement, and the purchase of consumer goods and automobiles; and construction loans and permanent mortgages for homes. It also offers debit card services, online banking services, safe deposit facilities, and automated teller fa cilities. As of July 14, 2011, Metro Bancorp operated 33 stores in the counties of Berks, Cumberland, Dauphin, Lancaster, Lebanon, and York. The company was formerly known as Pennsylvania Commerce Bancorp, Inc. and changed its name to Metro Bancorp, Inc. in June 2009. Metro Bancorp, Inc. was founded in 1984 and is headquartered in Harrisburg, Pennsylvania.
Advisors' Opinion:- [By Tim Melvin]
Metro Bancorp (METR) is one bank that might consider selling based on these metric. The company�� return on assets has consistently been well below its peer group, and the equity-to-asset ratio is just 8.46 — well below the 11 average across the United States.
Top 10 Supermarket Stocks To Buy For 2014: Titan Pharmaceuticals Inc (TTNP.OB)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion:- [By C.R. Jackson]
Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.
No comments:
Post a Comment